Investigating how tau protein affects brain cell function and toxicity
Tau-Mediated Regulation and Dysregulation of Protein Phosphatase 1
This study is looking into how a protein called tau behaves in diseases like Alzheimer's and frontotemporal dementia, with the hope of finding new ways to help protect brain cells from its harmful effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10771110 on NIH RePORTER |
What this research studies
This research explores the role of tau protein in neurodegenerative diseases like Alzheimer's and frontotemporal dementia. It focuses on understanding how abnormal modifications of tau lead to its aggregation and subsequent toxicity in brain cells. By using advanced techniques, including isolated axoplasm from squid giant axons, the study aims to uncover the molecular pathways through which tau disrupts normal signaling and contributes to neurodegeneration. The ultimate goal is to identify potential therapeutic targets that could mitigate the harmful effects of tau in these diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, frontotemporal dementia, or related tauopathies.
Not a fit: Patients with neurodegenerative diseases not associated with tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that modify tau's harmful effects, potentially improving outcomes for patients with neurodegenerative diseases.
How similar studies have performed: Previous research has shown promising results in targeting tau-related pathways, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Kanaan, Nicholas M — Michigan State University
- Study coordinator: Kanaan, Nicholas M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.